Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

July 12, 2021

Using Confidence Distributions to Manage Statistical Heterogeneity

Medical researchers and public health experts are becoming more reliant on meta-analyses to capture in summary form,...

Read article

December 18, 2019

Year-End Roundup: Your Favorite Blog Posts of 2019

With only two weeks left for this fabulous year to end, we would like to thank all our blog subscribers and new readers...

Read article

May 31, 2018

5 Reasons to Integrate MBMA Into Your Clinical Development Strategy

By Esha Senchaudhuri An important trend in clinical development involves integrating strategic pharmacometric analysis...

Read article

January 3, 2018

How Can We Tackle Heterogeneity in Meta-Analysis?

Health professionals and policy makers want to make healthcare decisions based on the relevant research evidence. The...

Read article